Cancer immunoediting by the innate immune system in the absence of adaptive immunity
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Cancer immunoediting is the process whereby immune cells protect against cancer formation by sculpting the immunogenicity of developing tumors. Although the full process depends on innate and adaptive immunity, it remains unclear whether innate immunity alone is capable of immunoediting. To determine whether the innate immune system can edit tumor cells in the absence of adaptive immunity, we compared the incidence and immunogenicity of 3'methylcholanthrene-induced sarcomas in syngeneic wild-type, RAG2(-/-), and RAG2(-/-)x γc(-/-) mice. We found that innate immune cells could manifest cancer immunoediting activity in the absence of adaptive immunity. This activity required natural killer (NK) cells and interferon γ (IFN-γ), which mediated the induction of M1 macrophages. M1 macrophages could be elicited by administration of CD40 agonists, thereby restoring editing activity in RAG2(-/-)x γc(-/-) mice. Our results suggest that in the absence of adaptive immunity, NK cell production of IFN-γ induces M1 macrophages, which act as important effectors during cancer immunoediting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In line with these findings, microbes may reverse the resistance to immunotherapy through reactivation of IFN-ɤ signaling pathways.”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [91]
Experimental — accuracy not yet measuredIn the citing paper
“IFN-ɤ, an important cytokine involved in antitumor immunity, could upregulate MHC expression on tumor cells and M1 macrophages and facilitate the recognition and elimination of transformed cells (91, 92).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“…for macrophages that is consistent with studies performed almost 40 yr ago, when it was shown that activated macrophages from infected mice (Hibbs et al., 1971) could kill syngeneic transformed murine embryonic fibroblasts, but not primary nontransformed murine embryonic fibroblasts (Hibbs…”
BackgroundTakahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673 · cited 1×
“Using the 3 methylcholanthrene (MCA) model of sarcomagenesis, we previously found that the immune system in WT mice could edit tumors more effectively than the immune system in RAG2 / mice (which lack adaptive immunity; Shankaran et al., 2001; Takahashi and Yamanaka, 2006), but we did not assess whether tumors from RA…”
MethodCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Self-citationMonocyte and macrophage heterogeneity
Gordon, S., & Taylor, P. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1733 · Cited by 5,190 · cited 4×
“M1 macrophages are activated classically via IFN- and function in the removal of intracellular pathogens (Gordon and Taylor, 2005).”
BackgroundResultInfluentialThe Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Self-citationThe Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Self-citationIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896 · cited 13×
“Tumor induction by MCA was performed as previously described (Smyth et al., 2000; Shankaran et al., 2001).”
BackgroundMethodResultInfluentialSelf-citationAlternative Activation of Macrophages: An Immunologic Functional Perspective
Martinez, F. O., Helming, L., & Gordon, S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132532 · Cited by 2,745 · cited 1×
“…characterized by quantitative PCR, using markers known to be associated with an M1-type phenotype (TNF and inducible nitric oxide synthase [iNOS]; Martinez et al., 2009) or with an M2-type phenotype (arginase and epithelial cadherin [eCAD]), growth arrest–specific gene 3 (Gas3; Ghassabeh et al.,…”
MethodDistinct role of macrophages in different tumor microenvironments
Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225 · cited 2×
“…that these macrophages were classically activated (Gordon and Taylor, 2005) M1 macrophages and performed immunophenotyping to detect the presence of tumor-associated M1 or M2 macrophages, known to have anti- or pro-tumor functions, respectively (Lewis and Pollard, 2006; Sica et al., 2008).”
BackgroundRAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement
Shinkai, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90029-c · Cited by 2,150 · cited 1×
“Genotyping was performed using PCR (for IL-2R c, following The Jackson Laboratories protocol [http://jaxmice.jax.org/strain/003174.html]) or by Southern blot for RAG2 (Shinkai et al., 1992).”
Method
Cited by
Items 301–348 of 348
Engineering NK Cells Towards Next Generation NK Cell Immunotherapy
Oei, V. Y. S. (2018) · NVA (Nasjonalt vitenarkiv)
Immunotherapy and immunosuppression in myeloid leukemia
Hallner, A. (2018) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Development of TCR-engineered iNKT cells for Cancer Immunotherapy
Umaña, J. M. (2018) · TSpace (University of Toronto)
Dynamics of natural killer cell homeostasis : implications for cell-based cancer Immunotherapy
Pfefferle, A. (2019) · Figshare
Harnessing Natural Killer Cells’ Killing Function in Cancer
Lim, J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-812034-7.00005-4
Wong, Y. Y., Riggan, L., Reyes, E. P., Huerta, C., Moldenhauer, M. R., & O’Sullivan, T. E. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.23.394353
Self-citationMacFawn, I. (2020) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.7778
Adoptive NK cell therapies in children with cancer: Clinical challenges and future possibilities
Nguyen, R., & Furman, W. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00018-7
You, R., Zou, X., Zhang, M., Zhang, W., Ding, X., Wang, X., Xu, H., Liu, Y., Ouyang, Y., Duan, C., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4054842
Current Immunotherapy of Melanoma
Loo, K. L., Wu, C., & DAUD, A. I. (2018) · Springer eBooks · doi:10.1007/978-3-319-78310-9_35
Faculty Opinions recommendation of Cellular backpacks for macrophage immunotherapy.
Young, H. A. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737846681.793575657
Darwin, E. (2013) · Jurnal Kesehatan Andalas · doi:10.25077/jka.v2i0.724
Das, A., & Garg, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-96128-8.00003-1
Cancer patient stratification based on patterns of immune infiltration
Schaafsma, E., Zhang, B., Zhao, Y., & Cheng, C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00027-7
Immunology of Cytokine Storm Syndromes: Natural Killer Cells
French, A. R., Cron, R. Q., & Cooper, M. A. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-59815-9_11
Zhu, Y., Cai, J., Suhandynata, R. T., & Bui, J. D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.05.685429
Self-citationZhu, X., He, L., Li, X., Pei, W., Yang, H., Zhong, M., Zhang, M., Lv, K., & Zhang, Y. (2023) · Figshare · doi:10.6084/m9.figshare.22615390
Zhu, X., He, L., Li, X., Pei, W., Yang, H., Zhong, M., Zhang, M., Lv, K., & Zhang, Y. (2023) · Figshare · doi:10.6084/m9.figshare.22615393
Zhu, X., He, L., Li, X., Pei, W., Yang, H., Zhong, M., Zhang, M., Lv, K., & Zhang, Y. (2023) · Figshare · doi:10.6084/m9.figshare.22615396
Zhu, X., He, L., Li, X., Pei, W., Yang, H., Zhong, M., Zhang, M., Lv, K., & Zhang, Y. (2023) · Figshare · doi:10.6084/m9.figshare.22615399
Tumor-Infiltrating Natural Killer Cells—Challenges and Strategies
Marquardt, N., Alici, E., & Meinke, S. (2025) · Springer eBooks · doi:10.1007/978-3-662-68816-8_70-1
CD28 : nouvelles données sur un récepteur majeur de la costimulation lymphocytaire T
Morin, S. O. (2017) · theses.fr (ABES) · doi:10.70675/cb01635fz2f63z43e2zad0cz210485c4c5cf
Role of immune and nervous system interaction : pre-clinical and clinical studies
Daoudlarian, D. (2018) · theses.fr (ABES) · doi:10.70675/77feff3azfefbz422az89bdzeafc45e09199
Low protein diet induced anti-cancer immune response
Bossowski, J. P. (2018) · theses.fr (ABES) · doi:10.70675/df1b8a94z84ccz47d6z9b67zcd24191657d6
Défauts fonctionnels des cellules NK en contexte de stimulation chronique
Marotel, M. (2019) · theses.fr (ABES) · doi:10.70675/1dcb97a5za482z4664zaaf6z62a53817eea9 · Cited by 1
Etude des mécanismes de contrôle des cellules tumorales par les cellules Natural Killer
Fenis, A. (2024) · theses.fr (ABES) · doi:10.70675/747c59caz7a79z4064z989cz9dd2bc8bd27e
Mercier‐Letondal, P. (2025) · theses.fr (ABES) · doi:10.70675/fb692847z0188z4b0czaf29za1e4d337e717
Cabral, F. V., Quílez-Alburquerque, J., Mooradian, O., Allen, D., Conn, A., & Hasan, T. G. (2026) · Neoplasia · doi:10.1016/j.neo.2026.101311
“As a result, the antimetastatic effects observed in this T-cell – deficient setting are likely driven by an enhanced innate immune response, even when the adaptive response is weak [24].”
An epigenetic four-lane route to camouflage for cancer cells
Galluzzi, L., Manic, G., & Vitale, I. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.05.017
Martin, C., Robert, J., Bernard, S., & Girard, A. (2026) · Asian journal of Current Research in Clinical Cancer · doi:10.51847/32pem7ihp4
E3 ubiquitin ligase NKLAM/RNF19b suppresses myc-driven B cell lymphomagenesis in Eμ-myc mice
Hoover, R. G., Matchett, E. C., & Kornbluth, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1874366
TACC3, correlated with immune cell infiltrates, is a novel prognostic biomarker in BRCA
Li, Z., Zhou, X., Wu, X., Li, H., & Zhou, C. (2026) · Medicine · doi:10.1097/md.0000000000049943
“[61,62] DCs are the most potent antigen-presenting cells, and their infiltration enhances the presentation of tumor-associated or tumor-specific antigens to T cells, thereby initiating primary immune responses.”
Han, X., Chen, Q., Li, K., Wu, J., Wang, A., Wang, Y., Zhao, H., & Liu, W. (2026) · Microsystems & Nanoengineering · doi:10.1038/s41378-026-01401-2 · Cited by 1
“On the other hand, NK-secreted IFN-γ reprograms macrophage polarization 10 .”
Yan, S., & Zhang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1952918
“Analogous to cancer immunoediting (66 – 68), glycoediting represents a dynamic process in which selective immune pressure may progressively shape leukemic populations toward states that evade innate immune recognition.”
Li, J., Wu, M., Xiong, X., Zhou, T., & Di, F. (2026) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2026.579105
Étude génétique et fonctionnelle des Interferon-producing Killer Dendritic Cells
Guimont‐Desrochers, F. (2012) · doi:10.71781/31981
Metadata
- Authors
- O’Sullivan, T., Saddawi-Konefka, R., Vermi, W., Koebel, C. M., Arthur, C., White, J. M., Uppaluri, R., Andrews, D. M., Ngiow, S. F., Teng, M. W. L., Smyth, M. J., Schreiber, R. D., & Bui, J. D.
- Affiliations
- University of California San Diego (US)
- Department of Pathology, University of California at San Diego, La Jolla, CA 92093 1
- University of Brescia (IT)
- Washington University in St. Louis (US)
- Center for Immunology, Department of Pathology and Immunology 3 and 4
- The University of Melbourne (AU)
- Corresponding author
- Bui, Jack D.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2012-08-27
- Volume
- 209
- Issue
- 10
- Pages
- 1869-1882
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3457735
- OpenAlex
- W2144577255
- Cited by
- 348
- References
- 58
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 24 · 2023: 31 · 2022: 22 · 2021: 30 · 2020: 29 · 2019: 25 · 2018: 32 · 2017: 30 · 2016: 27 · 2015: 23 · 2014: 21 · 2013: 29 · 2012: 6
- FWCI
- 11.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion, public-domain)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
- Funders
- Cancer Research Institute
- Concern Foundation
- Hartwell Foundation (CA157885)
- Ludwig Institute for Cancer Research
- Cancer Research Coordinating Committee
- National Institutes of Health (CA157885)
- Medical Research Council
- National Health and Medical Research Council
- National Cancer Institute (CA 107527, CA128893, K08CA128893, K08CA090403, R01CA043059, R01CA157885, CA-43059, R37CA043059, R01CA107527, CA157885)
- National Center for Research Resources (C06RR012466)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cancer immunoediting, innate immunity, natural killer cells, interferon-gamma, M1 macrophages, CD40 agonist, Rag2 knockout mice, tumor immunogenicity, adaptive immunity
- MeSH terms
- Animals, Histocompatibility Antigens Class II, DNA-Binding Proteins, Immunity, Innate, Interferon-gamma, Killer Cells, Natural, Macrophages, Neoplasms, Phenotype, Sarcoma, Transplantation, Isogeneic, Mice, Knockout, CD40 Antigens, Genetic Predisposition to Disease, Cell Line, Tumor, Mice, Interleukin Receptor Common gamma Subunit, Adaptive Immunity, Immunomodulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.